# Phase I/IIa Dose Ranging CHRONVAC-C® Study in Chronic HCV Patients

> **NCT00563173** · PHASE1,PHASE2 · UNKNOWN · sponsor: **Tripep AB** · enrollment: 12 (estimated)

## Conditions studied

- Chronic Hepatitis C Virus Infection

## Interventions

- **DRUG:** CHRONVAC-C®

## Key facts

- **NCT ID:** NCT00563173
- **Lead sponsor:** Tripep AB
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1,PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** UNKNOWN
- **Start date:** 2007-10
- **Primary completion:** 2010-04
- **Final completion:** 2010-04
- **Target enrollment:** 12 (ESTIMATED)
- **Last updated:** 2010-02-10

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00563173

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00563173, "Phase I/IIa Dose Ranging CHRONVAC-C® Study in Chronic HCV Patients". Retrieved via AI Analytics 2026-06-16 from https://api.ai-analytics.org/clinical/NCT00563173. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*